Board of directors

Martin Nicklasson

Chairman of the Board
Chairman of the Remuneration and Compensation Committee and of the Nomination Committee; member of the Audit Committee.

Elected to the Board in 2015 and regarded as an independent board member.

Special competencies
Extensive general management and research and development experience from AstraZeneca Plc and Swedish Orphan Biovitrum AB.

Current positions
Chairman of the board of Orexo AB and Kymab Ltd. Board member of Basilea Pharmaceutica Ltd.


Kirsten A. Drejer

Vice Chairman of the Board

Elected to the Board in 2018 and regarded as an independent board member.

Special competencies

More than 30 years of international experience in the pharmaceutical and biotech industry. Before co-founding Symphogen A/S in 2000, held several scientific and managerial positions at Novo Nordisk A/S.

Current positions
Chairman of the board of Antag Therapeutics, Bioneer and Resother Pharma. Board member of Bioporto, Lyhne & Co. and Alligator Bioscience AB.


Jeffrey Berkowitz

Board member
Member of the Audit Committee.

Elected to the Board in 2019 and regarded as an independent board member.

Special competencies
Global executive with extensive branded and generic pharmaceutical, retail pharmacy, wholesale drug distribution, specialty, payor and healthcare services leadership experience in P&L accountable roles.

Current positions
He is a member of the Board of Directors of H. Lundbeck A/S, Esperion Theraptics, Inc. and Infinity Pharmaceuticals, Inc.


Bernadette Connaughton

Board member
Elected to the Board in 2019 and regarded as an independent board member.

Special competencies
More than 30 years of global strategic, commercial and leadership expertise, and a broad perspective on the strategy, capabilities and governance required for successful execution in U.S. and international markets.


Leonard Kruimer

Board member
Chairman of the Audit Committee.

Elected to the Board in 2019 and regarded as an independent board member.

Special competencies
More than 30 years of experience in corporate finance, planning and strategy, including 15 years in senior executive positions in private and publicly listed biotechnology companies.


Alain Munoz

Board member
Member of the Remuneration and Compensation Committee.

Elected to the Board in 2005 (resigned in 2006, was re-elected in 2007) and regarded as an independent board member.

Special competencies
Physician qualified cardiology and intensive care. Experience in the pharmaceutical industry at senior management level. Served as SVP for international development in the Sanofi Group and in the pharmaceutical division of Fournier Laboratories.

Current positions
Independant Board member of Valneva SEHybrigenics, , Auris medical and Oxthera, adviser to Kurma Biofund.


Michael J. Owen

Board member
Member of the Remuneration and Compensation Committee.

Elected to the Board in 2012 and regarded as an independent board member.

Special competencies
Research experience focusing on the immune system and more than 150 publications. Has held several leading positions at GlaxoSmithKline, most recently as SVP and head of biopharmaceuticals research.

Current positions
Chairman of the board of Ossianix Inc., and is a member of the board of Avacta Group plc, ReNeuron Group plc, Sareum Holdoings plc, Iksuda Therapeutics and GammaDelta Therapeutics. He is an adviser to the CRT Pioneer Fund.


Hanne Heidenheim Bak

Employee-elected board member
Elected to the Board in 2012-2014 and re-elected in 2016.

Current positions
Senior Project Director, GI, External Relations and Collaborations.


Jens Peter Stenvang

Employee-elected board member
Elected to the Board in 2014, and re-elected in 2018.

Current positions
Laboratory Technician (Biology).